Cetuximab is a therapeutic chimeric monoclonal antibody that is used as a targeted therapy for metastatic colorectal cancer (mCRC) and cancer of the head and neck Enzene Biosciences has launched Cetuximab as the first biosimilar to cancer. Sold under the brand name Erbitux, Cetuximab is a therapeutic chimeric monoclonal antibody that is used as a targeted therapy for metastatic colorectal cancer (mCRC) and cancer of the head and neck, with eight weeks of treatment costing about $30,000 for a single patient.
Enzene
